{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:51Z","timestamp":1787242431754,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"vor","delay-in-days":309,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Knowledge of the impact of the gut microbiome on conditions other than Clostridium difficile infection has been rapidly increasing, and the potential usefulness of fecal microbiota transplantation (FMT) in these indications is being explored. The need to exclude donors with an increased risk of these diseases has left uncertainties regarding the cost and feasibility of donor screening. The aim of this study was to compare our experience to other donor-screening programs and report the costs associated with establishing a donor-screening program, for the treatment of metabolic syndrome-related conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty-six potential donors (PDs) had their medical histories and physical examinations undertaken by a physician. Blood, stool, and urine were screened for 31 viral, bacterial, fungal, and protozoan agents in addition to biochemical characteristics. The price of advertising, doctor\u2019s visits and diagnostic tests were calculated to determine the cost of finding a donor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the PDs screened, 5 of 46 passed the history, examination, blood, stool, and urine tests. The most common reasons for exclusion included a body mass index &amp;gt;25 or the detection of Blastocystis hominis, Dientamoeba fragilis, or Helicobacter pylori. Four of five eligible donors had subsequent travel or illness that contraindicated donation, so only 1 of 46 PDs was suitable. The total cost for finding a single suitable donor was $15190 US dollars. This screening was performed in Canada, and costs in the United States would be substantially higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>New potential therapeutic uses for FMT have created a demand for stricter exclusion criteria for donors. This study illustrates that screening many individuals to find a donor and the subsequent associated costs may make central processing and shipment a more reasonable alternative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofx243","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T08:07:12Z","timestamp":1509955632000},"source":"Crossref","is-referenced-by-count":52,"title":["Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases"],"prefix":"10.1093","volume":"4","author":[{"given":"Laura J","family":"Craven","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, London, Ontario, Canada"},{"name":"Lawson Health Research Institute, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nair Parvathy","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St. Joseph\u2019s Health Care, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Tat-Ko","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, London, Ontario, Canada"},{"name":"Division of Urology, Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"},{"name":"Lawson Health Research Institute, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, London, Ontario, Canada"},{"name":"Lawson Health Research Institute, London, Ontario, Canada"},{"name":"Department of Infectious Disease, St. Joseph\u2019s Health Care, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"2020081005280848100_CIT0001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/M16-0271","article-title":"Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial","volume":"165","author":"Kelly","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020081005280848100_CIT0002","first-page":"24","article-title":"Fecal microbiota transplantation: a review of emerging indications beyond relapsing Clostridium difficile toxin colitis","volume":"11","author":"Jung Lee","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2020081005280848100_CIT0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12321","article-title":"The intestinal microbiome in type 1 diabetes","volume":"177","author":"Dunne","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2020081005280848100_CIT0004","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/j.gastro.2013.02.043","article-title":"Consumption of fermented milk product with probiotic modulates brain activity","volume":"144","author":"Tillisch","year":"2013","journal-title":"Gastroenterology"},{"key":"2020081005280848100_CIT0005","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMcpc1400842","article-title":"Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea","volume":"371","author":"Hohmann","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081005280848100_CIT0006","article-title":"Fecal microbiota therpay used in the treatment of Clostridium difficile infection not responsive to conventional therapies","author":"Health Canada","year":"2015","journal-title":"Guidance Document"},{"key":"2020081005280848100_CIT0007","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/367657","article-title":"Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube","volume":"36","author":"Aas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020081005280848100_CIT0008","doi-asserted-by":"crossref","first-page":"e00458","DOI":"10.7554\/eLife.00458","article-title":"Cohabitating family members share microbiota with one another and with their dogs","volume":"2","author":"Song","year":"2013","journal-title":"Elife"},{"key":"2020081005280848100_CIT0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40168-015-0140-3","article-title":"Optimal screening and donor management in a public stool bank","volume":"3","author":"Kazerouni","year":"2015","journal-title":"Microbiome"},{"key":"2020081005280848100_CIT0010","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/MIB.0000000000000405","article-title":"Donor recruitment for fecal microbiota transplantation","volume":"21","author":"Paramsothy","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2020081005280848100_CIT0011","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cid\/civ994","article-title":"Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection","volume":"62","author":"Costello","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081005280848100_CIT0012","article-title":"Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection","author":"Tariq","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"2020081005280848100_CIT0013","volume-title":"Quality and safety program","author":"OpenBiome","year":"2017"},{"key":"2020081005280848100_CIT0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"2020081005280848100_CIT0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"2020081005280848100_CIT0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.2015.18100","article-title":"Expanded evidence for frozen fecal microbiota transplantation for Clostridium difficile infection: a fresh take","volume":"315","author":"Malani","year":"2016","journal-title":"JAMA"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/4\/ofx243\/33623842\/ofx243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/4\/ofx243\/33623842\/ofx243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T05:32:41Z","timestamp":1597037561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofx243\/4596664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofx243","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2017]]},"article-number":"ofx243"}}